Ortho Regenerative Technologies Inc (CSE:ORTH) CEO Phillipe Deschamps tells Proactive it has fully activated half of the 10 clinical trial sites involved in its upcoming Phase 1/2 rotator cuff tear repair trial evaluating the company’s novel soft tissue repair regenerative technology.
Sites involved in the study are the Rothman Institute in Pennsylvania, the OrthoIndy Research Foundation in Indiana, University Orthopedics, in Pennsylvania, Tucson Orthopedics in Arizona, and the Holy Cross Orthopedic Institute in Florida, with site activation imminent at the OrthoVirginia Institute in Virginia.